

**WG21-83**

**THE NATIONAL HEALTH  
SERVICE (WALES) ACT 2006**

**The Pharmaceutical Services (Fees  
for Applications) (Wales)  
Directions 2021**

*Made* 1 October 2021

*Coming into force* 2 October 2021

The Welsh Ministers in exercise of the powers conferred on them by sections 85 and 203(9) of the National Health Service (Wales) Act 2006<sup>(1)</sup>, and after consulting in accordance with section 85(3) of that Act with such organisations as the Welsh Ministers consider appropriate that appear to the Welsh Ministers to represent persons providing pharmaceutical services and such organisations as the Welsh Ministers consider appropriate that appear to represent Local Health Boards, give the following Directions.

**Title, application and commencement**

**1.**—(1) The title of these Directions is the Pharmaceutical Services (Fees for Applications) (Wales) Directions 2021.

(2) These Directions are given to Local Health Boards.

(3) These Directions come into force on 2 October 2021.

**Interpretation**

**2.**—(1) Where reference is made in these Directions to a numbered regulation, it is to the regulation in the National Health Service (Pharmaceutical Services) (Wales) Regulations 2020<sup>(2)</sup> bearing that number.

---

(1) 2006 c. 42.

(2) S.I. 2020/1073 (W. 241).

(2) Expressions used in these Directions and in the National Health Service (Pharmaceutical Services) (Wales) Regulations 2020 have the same meaning as in those Regulations.

### **Fees**

**3.**—(1) A Local Health Board must charge the specified fee in paragraph (2) to each person who makes an application under regulation 15(1) (Applications to be included in or make amendment to a pharmaceutical list) or regulation 18 (applications for preliminary consent and effect of preliminary consent), except that—

- (a) no fee is payable by a person in respect of an application under regulation 15(1)(b)(ii) which satisfies the conditions in regulation 21(1) (Applications involving temporary relocation); and
- (b) no fee is payable by a person who has been granted preliminary consent under regulation 18 and who then makes a subsequent application under regulation 15(1)(a) or 15(1)(b)(i) which satisfies the requirements of regulation 18(6).

(2) The specified fee is £600, except where paragraph (3) applies.

(3) In the case of applications under regulation 15(1)(a), (b)(i) or (ii), where the conditions in regulation 22(1) (Applications involving a change of ownership) are satisfied, the specified fee—

- (a) if the applicant is already included in the Local Health Board's pharmaceutical list in respect of other premises, is £60; or
- (b) if the applicant is not already included in the Local Health Board's pharmaceutical list in respect of other premises, is £100.

### **Validity of applications where a fee is payable**

**4.** Where a Local Health Board charges a fee in relation to an application by virtue of these Directions, that application is only valid if that fee has been paid.

### **Revocation of the Pharmaceutical Services (Fees for Applications) (Wales) Directions 2013**

**5.** The Pharmaceutical Services (Fees for Applications) (Wales) Directions 2013(1) are revoked.

A handwritten signature in black ink, appearing to read 'A Slade', is positioned at the top of the page.

**Signed by Alex Slade, Deputy Director, Primary  
Care and Health Science under the authority of the  
Minister for Health and Social Services, one of the  
Welsh Ministers**

**Date: 1 October 2021**